Codexis, Inc. CDXS

Company Overview

Codexis, Inc. is a U.S.-based biotechnology company focused on developing and engineering enzymes for applications across the pharmaceutical manufacturing, life sciences, and industrial biotechnology sectors. The company operates primarily within the enzyme engineering and synthetic biology industries, using its proprietary protein engineering platform to optimize enzymes for improved performance, efficiency, and scalability. Codexis generates revenue through product sales, research and development collaborations, licensing agreements, and milestone payments associated with partnered programs.

The company’s core business historically centered on supplying engineered enzymes used in the manufacture of active pharmaceutical ingredients for major biopharmaceutical companies. In recent years, Codexis expanded into nucleic acid synthesis and genomic medicine tools, particularly through engineered enzymes used in RNA and DNA applications. A distinguishing strategic advantage is its proprietary CodeEvolver® technology platform, which enables rapid enzyme optimization through directed evolution techniques. Codexis was founded in 2002 and evolved from an industrial biocatalysis company into a broader biotechnology platform company serving pharmaceutical manufacturing and emerging genomic medicine markets.